Lantheus Holdings Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Lantheus Holdings Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.
Executive BD thesis
Lantheus Holdings is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 98 records at the decision date. The lead returned asset is [18F]DCFPyL, associated with PSMA and PSMA-Positive Prostatic Cancer, Prostatic Cancer, Renal Cell Carcinoma, Adenocarcinoma of prostate, at Approved. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.
A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | [18F]DCFPyL | Lantheus Holdings, Inc. | Approved | Pipeline record: PSMA; PSMA-Positive Prostatic Cancer, Prostatic Cancer, Renal Cell Carcinoma, Adenocarcinoma of prostate. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium | Approved asset with PSMA exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 2 | Florbetaben F-18 | Lantheus Holdings, Inc. | Approved | Pipeline record: APP; Alzheimer Disease, Cognitive Dysfunction, Diagnostic agents, Immunoglobulin Light-Chain Amyloidosis. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan | Approved asset with APP exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 3 | Perflutren lipid microsphere | Lantheus Medical Imaging, Inc. | Approved | Pipeline record: target not returned; Contrast agents, Chronic Exertional Compartment Syndrome, Kidney Diseases, Pyonephrosis. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Lantheus Announces Sale of SPECT Business to SHINE Technologies | Approved asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 4 | XENON XE-133 | Lantheus Medical Imaging, Inc. | Approved | Pipeline record: target not returned; indication not returned. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium | Approved asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 5 | Flurpiridaz F 18 | Lantheus Holdings, Inc. | NDA/BLA | Pipeline record: Mcl-1 x NQO1; Cardiovascular Diseases, Coronary Artery Disease, Ischemia. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan | NDA/BLA asset with Mcl-1 x NQO1 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
Shortlist interpretation. Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2026-05-26 | Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium | Active | Not disclosed |
| 2025-09-24 | Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan | Active | Not disclosed |
| 2025-05-06 | Lantheus Announces Sale of SPECT Business to SHINE Technologies | Active | Not disclosed |
Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.
Financial capacity and partnering pressure
- Lantheus Holdings, Inc. - 2021 Annual report: Lantheus Holdings, Inc. - 2021 Annual report Item 6. Selected Financial Data For a comparison of our results of operations for the fiscal years ended December 31, 2020 and December 31, 2019, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021. Liquidity and Capital Resources Cash Flows The following table provides information regarding our cash flows: For a discussion of our liquidity and capital resources related to our cash flow activities for the fiscal year ended December 31, 2019, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021. Net
- Lantheus Holdings, Inc. - 2022 Annual report: Lantheus Holdings, Inc. - 2022 Annual report Item 1. Business For the years ended December 31, 2022, 2021 and 2020, we invested $311.7 million, $45.0 million and $32.8 million in research and development (“R&D”), respectively, primarily related to our clinical development candidates. For the year ended December 31, 2022, we recognized $260.0 million of R&D expense related to the upfront payments to POINT. In addition to our clinical development group, our R&D team also includes our Medical Affairs and Medical Information functions, which educate physicians on the scientific aspects of our commercial products and the approved indications. See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with our strategic partnerships and clinical development programs. Distribution, Marketing and Sales The following table sets forth certain key market information for
- Lantheus Holdings, Inc. - 2023 Annual report: Lantheus Holdings, Inc. - 2023 Annual report Liquidity and Capital Resources Cash Flows The following table provides information regarding our cash flows: For a discussion of our liquidity and capital resources related to our cash flow activities for the fiscal year ended December 31, 2021, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023. Net Cash Provided by Operating Activities Net cash provided by operating activities of $305.3 million during the year ended December 31, 2023 was primarily comprised of net income adjusted for the net effect of non-cash items such as impairment of long-lived assets, depreciation, amortization and accretion expense, gain on sale of our RELISTOR royalty asset, deferred income ta
Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.
Current-awareness events and outreach triggers
The Current Awareness news_search call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.
The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.
IP and freedom-to-operate risk screen
The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.
Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.
Recommended deal structures
- Regional license: useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.
- Co-development: appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.
- Option-to-license: reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.
- Research or platform collaboration: suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.
- Structured financing: may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.
Outreach rationale and first-contact plan
- Identify the decision owner. Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.
- Lead with one verifiable gap. Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.
- Attach a concise evidence package. Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.
- Offer a structure. Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.
- Define the diligence sequence. Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.
Decision memo
ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH. Lantheus Holdings offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.
Required next diligence: refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 22 July 2026. Counts, ownership and statuses may change as records update.
